SCHEMBL19426112

SCHEMBL19426112

CC(=O)C(NO)c1cc(O)c(O)c(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ ALOX12 P18054 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ HIF1A Q16665 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ TTR P02766 1/20 0.32
▸ KIF11 P52732 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ NFKB1 P19838 1/20 0.31
▸ XDH P47989 1/20 0.31
▸ GFER P55789 1/20 0.31
▸ NFKB2 Q00653 1/20 0.31
▸ RELA Q04206 1/20 0.31
▸ FUT7 Q11130 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19426169 0.84 CYP1A2 (0.36) CYP1A2CYP2C9ALOX15ALOX12CYP2C19
SCHEMBL19426110 0.81 ADRB1 (0.45) KDM4ELMNAPOLBGAANFKB1
SCHEMBL19426174 0.74 TDP1 (0.43) CYP1A2ALOX15ALOX12CYP2C19SMN1; SMN2
SCHEMBL19426171 0.72 ALOX15 (0.34) CYP1A2ALOX15ALOX12CYP2C19HSD17B10
SCHEMBL15631294 0.70 GABRA1 (0.59) CYP1A2CYP2C9ALOX15ALOX12CYP2C19
SCHEMBL11157172 0.68 HSD17B10 (0.43) CYP1A2CYP2C9ALOX15ALOX12CYP2C19
SCHEMBL19426106 0.67 YARS1 (0.32) ALOX12HSD17B10KDM4EPOLBGAA
SCHEMBL19426179 0.66 POLB (0.41) CYP1A2CYP2C9ALOX15ALOX12CYP2C19
SCHEMBL19426173 0.66 ADRB1 (0.43) CYP1A2SMN1; SMN2HIF1AHSD17B10KDM4E
SCHEMBL19426108 0.66 ADRA2A (0.45) HSD17B10KDM4ETDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170281532-A1 2 SUBSTITUTED CEPHEM COMPOUNDS GLAXO GROUP LIMITED (GB) 2017-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281532-A1 2 SUBSTITUTED CEPHEM COMPOUNDS CEP170, CES2, CMBL CYP1A2 184/4885CYP2C9 180/4885ALOX15 4255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback